Adoption ChallengesDespite positive reactions, it will take time for payors to adopt the new formulation, and the full impact is unlikely to be realized immediately.
Operational RisksNear-term uncertainty exists due to a manufacturing pause on the key revenue-driving asset EGRIFTA SV and uncertainty regarding the expansion of the company's pipeline/portfolio.
Revenue UncertaintyThe shortage resulted in an expected $10M — $12M one-time reduction in revenue, and weaker sales are anticipated in the short term.